Latest news

• Another blow for BMS in first-line NSCLC as it pulls EU filing

  irrespective of their expression of the PD-L1 biomarker. There has been further bad news for BMS after its recently-acquired Celgene unit withdrew a marketing application for Idhifa (enasidenib) as

• Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

  If approved, the CC-486 will round out an AML franchise at Celgene that along with Vidaza also includes Agios-partnered  Idhifa(enasidenib), a targeted second-line therapy for patients with

• Novartis gets EU nod for leukaemia drug Rydapt

  or AML with myelodysplasia-related changes (AML-MRC) – while Celgene/Agios claimed approval for Idhifa (enasidenib) as a treatment for AML patients with the IDH2 mutation.

• Celgene, Agios get FDA OK for leukaemia drug Idhifa

  Idhifa ( enasidenib or AG-221) has been cleared for the treatment of relapsed or refractory acute myeloid leukaemia (AML) in patients with an IDH2 mutation, a group that accounts for somewhere ... At Celgene, enasidenib will slot into its blood cancer

• Celgene bags US priority review for cancer metabolism drug

  First approval for enasidenib could be just six months away. Celgene could be just six months away from getting its first approval for enasidenib, a first-in-class drug for acute ... Celgene filed for approval of enasidenib as a treatment for relapsed,